Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
23 juin 2021 07h30 HE
|
Cerecor Inc.
ROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...
Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance
07 juin 2021 07h00 HE
|
Cerecor Inc.
An initial tranche of $20 million drawn at the loan closingFunds ongoing clinical development of key investigational product candidatesFinancing provides flexibility and extends runway through...
Cerecor to Participate in Upcoming Investor Conferences
17 mai 2021 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates
13 mai 2021 07h00 HE
|
Cerecor Inc.
Announced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19...
FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19
11 mai 2021 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease
05 mai 2021 07h00 HE
|
Cerecor Inc.
Initial data anticipated in the third quarter of 2021Top-line data from the ongoing Phase 1b proof of concept clinical trial in relapsed or refractory multiple myeloma patients anticipated in the...
Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
29 mars 2021 07h00 HE
|
Cerecor Inc.
Expanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indications including severe pediatric onset inflammatory bowel disease and ARDS...
Cerecor Reports 2020 Financial Results and Provides Business Updates
08 mars 2021 16h01 HE
|
Cerecor Inc.
•Announced CERC-002 significantly reduced respiratory failure and mortality in Phase 2 clinical trial in patients hospitalized with COVID-19 ARDS •Improved financial position with $18.9M of cash on...
Cerecor to Present at Upcoming Investor Conferences
04 mars 2021 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and...
Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS
02 mars 2021 07h00 HE
|
Cerecor Inc.
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in reducing respiratory failure and mortality at Day...